Crown Laboratories, Inc., a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance Therapeutics, Inc., a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings.
Jeff Bedard, Founder and Chief Executive Officer of Crown commented, “We are excited to officially welcome Revance to the Crown family. This acquisition strengthens our leadership position and enhances our ability to deliver innovative solutions to customers, with what we believe is a comprehensive portfolio that represents the three pillars of facial aesthetics – relax, restore, and regenerate – and we will support these offerings with a highly trained and experienced sales force. We are well-positioned to become a global leader in the aesthetics and skincare industry and will leverage our combined resources to create long-term value for our stakeholders.”
Also Read: PHC and CCRM Collaborate on T-Cell Expansion Culture
On behalf of Hildred, Co-Founders and Managing Partners Andrew Goldman and David Solomon said, “We are thrilled to celebrate the successful completion of this transaction and to commence the integration of two innovative companies that we believe will create a leading player in the dynamic skincare and aesthetics markets. Crown remains committed to providing healthcare providers and aesthetic practices with outstanding science-based products. We are excited to bring together Revance’s and Crown’s aesthetic offerings, and we look forward to continuing Revance’s relationship with Teoxane to grow the RHA® Collection by Teoxane in the U.S. market.”
Source: Businesswire